Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: To assess and compare the effects of candesartan or lisinopril, or both, on blood pressure and urinary albumin excretion in patients with microalbuminuria, hypertension, and type 2 diabetes. DESIGN: Prospective, randomised, parallel group, double blind study with four week placebo run in period and 12 weeks' monotherapy with candesartan or lisinopril followed by 12 weeks' monotherapy or combination treatment. SETTING: Tertiary hospitals and primary care centres in four countries (37 centres). PARTICIPANTS: 199 patients aged 30-75 years. INTERVENTIONS: Candesartan 16 mg once daily, lisinopril 20 mg once daily. MAIN OUTCOME MEASURES: Blood pressure and urinary albumin:creatinine ratio. RESULTS: At 12 weeks mean (95% confidence interval) reductions in diastolic blood pressure were 9.5 mm Hg (7.7 mm Hg to 11.2 mm Hg, P<0.001) and 9.7 mm Hg (7.9 mm Hg to 11.5 mm Hg, P<0.001), respectively, and in urinary albumin:creatinine ratio were 30% (15% to 42%, P<0.001) and 46% (35% to 56%, P<0.001) for candesartan and lisinopril, respectively. At 24 weeks the mean reduction in diastolic blood pressure with combination treatment (16.3 mm Hg, 13.6 mm Hg to 18.9 mm Hg, P<0. 001) was significantly greater than that with candesartan (10.4 mm Hg, 7.7 mm Hg to 13.1 mm Hg, P<0.001) or lisinopril (mean 10.7 mm Hg, 8.0 mm Hg to 13.5 mm Hg, P<0.001). Furthermore, the reduction in urinary albumin:creatinine ratio with combination treatment (50%, 36% to 61%, P<0.001) was greater than with candesartan (24%, 0% to 43%, P=0.05) and lisinopril (39%, 20% to 54%, P<0.001). All treatments were generally well tolerated. CONCLUSION: Candesartan 16 mg once daily is as effective as lisinopril 20 mg once daily in reducing blood pressure and microalbuminuria in hypertensive patients with type 2 diabetes. Combination treatment is well tolerated and more effective in reducing blood pressure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1997) · Archives of Internal Medicine · doi:10.1001/archinte.1997.00440420033005 · Cited by 3,777
(1999) · Journal of Hypertension · doi:10.1097/00004872-199917020-00001 · Cited by 3,695
Improving the Quality of Reporting of Randomized Controlled Trials: The CONSORT Statement
Begg, C. (1996) · JAMA · doi:10.1001/jama.1996.03540080059030 · Cited by 3,127
(2000) · PubMed · Cited by 2,095
Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes
Chaturvedi, N., Sjolie, A.-K., Stephenson, J. M., Abrahamian, H., Keipes, M., Castellarin, A., Rogulja-Pepeonik, Z., & Fuller, J. H. (1998) · The Lancet · doi:10.1016/s0140-6736(97)06209-0 · Cited by 743
Cha, M., Eastwaad, S., Hartan, R., Maher, D., Olkin, I., Pitkin, R., Rennie, D., Schulz, K. F., Simel, D. L., & Straup, D. F. (1996) · Cited by 737
Pathogenesis, prevention, and treatment of diabetic nephropathy
Cooper, M. E. (1998) · The Lancet · doi:10.1016/s0140-6736(98)01346-4 · Cited by 560
Self-citation
Cited by
Mancia, G., De Backer, G., Dominiczak, A., Cifkova, R., Fagard, R., Germano, G., Grassi, G., Heagerty, A. M., Kjeldsen, S. E., Laurent, S., et al. (2007) · Journal of Hypertension · doi:10.1097/hjh.0b013e3281fc975a · Cited by 5,824
Mancia, G., Fagard, R., Narkiewicz, K., Redón, J., Zanchetti, A., Böhm, M., Christiaens, T., Cifkova, R., De Backer, G., Dominiczak, A., et al. (2013) · Journal of Hypertension · doi:10.1097/01.hjh.0000431740.32696.cc · Cited by 5,655
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
Standards of medical care in diabetes—2013
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc13-s011 · Cited by 4,369
Standards of medical care in diabetes 2010
American Diabetes Association (2010) · Diabetes Care · doi:10.2337/dc10-s011 · Cited by 3,470
Standards of medical care in diabetes—2011
American Diabetes Association (2011) · Diabetes Care · doi:10.2337/dc11-s011 · Cited by 2,880
Type 2 diabetes: principles of pathogenesis and therapy
Stumvoll, M., Goldstein, B. J., & van Haeften, T. W. (2005) · The Lancet · doi:10.1016/s0140-6736(05)61032-x · Cited by 2,662
Authors/Task Force Members:, Mancia, G., De Backer, G., Dominiczak, A., Cifkova, R., Fagard, R., Germano, G., Grassi, G., Heagerty, A. M., Kjeldsen, S. E., et al. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehm236 · Cited by 2,384
Standards of Medical Care in Diabetes—2012
(2012) · Diabetes Care · doi:10.2337/dc12-s011 · Cited by 2,240
Standards of Medical Care in Diabetes—2009
American Diabetes Association (2009) · Diabetes Care · doi:10.2337/dc09-s013 · Cited by 2,167
Diabetic nephropathy: diagnosis, prevention, and treatment
Gross, J. L., de Azevedo, M. J., Silveiro, S. P., Canani, L. H., Caramori, M. L., & Zelmanovitz, T. (2005) · Diabetes Care · doi:10.2337/diacare.28.1.164 · Cited by 1,839
Standards of Medical Care in Diabetes 2014
(2014) · Majmaah Journal of Health Sciences · doi:10.12816/0004790 · Cited by 1,465
Thomas, M. C., Brownlee, M., Susztak, K., Sharma, K., Jandeleit-Dahm, K. A. M., Zoungas, S., Rossing, P., Groop, P.-H., & Cooper, M. E. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.18 · Cited by 1,230
Self-citationOxidative Stress as a Major Culprit in Kidney Disease in Diabetes
Forbes, J. M., Coughlan, M. T., & Cooper, M. E. (2008) · Diabetes · doi:10.2337/db08-0057 · Cited by 1,203
“To date, the most effective treatments for progressive diabetic nephropathy appear to be antihypertensive agents, particularly those that target the reninangiotensin system (RAS), such as ACE inhibitors, angiotensin receptor-1 antagonists, or their combination (2).”
BackgroundSelf-citationAliskiren Combined with Losartan in Type 2 Diabetes and Nephropathy
Parving, H.-H., Persson, F., Lewis, J. B., Lewis, E. J., & Hollenberg, N. K. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708379 · Cited by 1,098
American Diabetes Association (2004) · Diabetes Care · doi:10.2337/diacare.27.2007.s79 · Cited by 1,042
Nakao, N., Yoshimura, A., Morita, H., Takada, M., Kayano, T., & Ideura, T. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12229-5 · Cited by 970
RetractedKunz, R., Friedrich, C., Wolbers, M., & Mann, J. F. E. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-1-200801010-00190 · Cited by 717
Diabetic nephropathy – complications and treatment
Lim, A. (2014) · International Journal of Nephrology and Renovascular Disease · doi:10.2147/ijnrd.s40172 · Cited by 583
Nephropathy in Patients with Type 2 Diabetes
Remuzzi, G., Schieppati, A., & Ruggenenti, P. (2002) · New England Journal of Medicine · doi:10.1056/nejmcp011773 · Cited by 587
The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease
Remuzzi, G., Perico, N., Macia, M., & Ruggenenti, P. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.09911.x · Cited by 505
Chaturvedi, N., Porta, M., Klein, R., Orchard, T., Fuller, J., Parving, H. H., Bilous, R., & Sjølie, A. K. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61412-9 · Cited by 451
Douglas, J. G. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.5.525 · Cited by 438
Guidelines for the management of chronic kidney disease
Levin, A., Hemmelgarn, B., Culleton, B., Tobe, S., McFarlane, P., Ruzicka, M., Burns, K., Manns, B., White, C., Madore, F., et al. (2008) · Canadian Medical Association Journal · doi:10.1503/cmaj.080351 · Cited by 420
The renin-angiotensin-aldosterone system and the kidney: effects on kidney disease
Brewster, U. C., & Perazella, M. A. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2003.09.034 · Cited by 390
Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: Effects of ACEI and ARB
Onozato, M. L., Tojo, A., Goto, A., Fujita, T., & Wilcox, C. S. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00123.x · Cited by 373
Schrijvers, B. F., De Vriese, A. S., & Flyvbjerg, A. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0018 · Cited by 353
Matchar, D. B., McCrory, D. C., Orlando, L. A., Patel, M. R., Patel, U. D., Patwardhan, M. B., Powers, B., Samsa, G. P., & Gray, R. N. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-1-200801010-00189 · Cited by 348
The Treatment of Hypertension in Adult Patients With Diabetes
Arauz-Pacheco, C., Parrott, M. A., & Raskin, P. (2002) · Diabetes Care · doi:10.2337/diacare.25.1.134 · Cited by 326
The RAAS in the pathogenesis and treatment of diabetic nephropathy
Ruggenenti, P., Cravedi, P., & Remuzzi, G. (2010) · Nature Reviews Nephrology · doi:10.1038/nrneph.2010.58 · Cited by 319
Rossing, K., Schjoedt, K. J., Smidt, U. M., Boomsma, F., & Parving, H.-H. (2005) · Diabetes Care · doi:10.2337/diacare.28.9.2106 · Cited by 299
Diabetic nephropathy: diagnosis and treatment
Fineberg, D., Jandeleit-Dahm, K. A. M., & Cooper, M. E. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.184 · Cited by 295
Self-citationWolf, G., & Ritz, E. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00145.x · Cited by 289
Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease
Garg, J. P., & Bakris, G. L. (2002) · Vascular Medicine · doi:10.1191/1358863x02vm412ra · Cited by 278
Microalbuminuria, blood pressure and diabetic renal disease: origin and development of ideas
Mogensen, C. E. (1999) · Diabetologia · doi:10.1007/s001250051151 · Cited by 274
Self-citationPotassium Homeostasis and Renin-Angiotensin-Aldosterone System Inhibitors
Weir, M. R., & Rolfe, M. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.07821109 · Cited by 265
Mechanisms of progression of chronic kidney disease
Fogo, A. B. (2007) · Pediatric Nephrology · doi:10.1007/s00467-007-0524-0 · Cited by 263
Chen, S., Jim, B., & Ziyadeh, F. N. (2003) · Seminars in Nephrology · doi:10.1053/s0270-9295(03)00132-3 · Cited by 256
Makani, H., Bangalore, S., Desouza, K. A., Shah, A., & Messerli, F. H. (2013) · BMJ · doi:10.1136/bmj.f360 · Cited by 244
for the ORIENT study investigators, Imai, E., Chan, J. C. N., Ito, S., Yamasaki, T., Kobayashi, F., Haneda, M., & Makino, H. (2011) · Diabetologia · doi:10.1007/s00125-011-2325-z · Cited by 236
“These beneficial renal effects of olmesartan were in agreement with previous findings [21–25].”
ResultManagement of Glomerular Proteinuria: A Commentary
Wilmer, W. A., Rovin, B. H., Hebert, C. J., Rao, S. V., Kumor, K., & Hebert, L. A. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000100145.27188.33 · Cited by 217
RAS inhibition in hypertension
Ibrahim, M. M. (2006) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1001960 · Cited by 114
Sasso, F. C., Carbonara, O., Persico, M., Iafusco, D., Salvatore, T., D’Ambrosio, R., Torella, R., & Cozzolino, D. (2002) · Diabetes Care · doi:10.2337/diacare.25.11.1909 · Cited by 73
Sex-specific long-term blood pressure regulation: Modeling and analysis
Leete, J., & Layton, A. T. (2019) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2018.11.002 · Cited by 58
Feng, Y., Huang, R., Kavanagh, J., Li, L., Zeng, X., Li, Y., & Fu, P. (2019) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-018-00321-5 · Cited by 53
Type 2 diabetes: RENAAL and IDNT–the emergence of new treatment options
Sica, D. A., & Bakris, G. L. (2002) · The Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2002.00749.x · Cited by 49
Varughese, G. I., & Lip, G. Y. H. (2005) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1001833 · Cited by 25
“15 In the CALM (Candesartan and Lisinopril Microalbuminuria) study, addition of an ARB to an ACE inhibitor did achieve added benefits on blood pressure and microalbuminuria”
Influence of microalbuminuria in achieving blood pressure goals
Duka, I., & Bakris, G. (2008) · Current Opinion in Nephrology and Hypertension · doi:10.1097/mnh.0b013e328309a497 · Cited by 18
MORIMOTO, S., MAKI, K., AOTA, Y., SAKUMA, T., & IWASAKA, T. (2008) · Hypertension Research · doi:10.1291/hypres.31.1603 · Cited by 17
Grøn sælen, M., Katrine prøsch, L., Gudmundsdottir, H., Dyrbekk, D., Helge Hunderi, O., Arnesen, E., Paulsen, D., Skjønsberg, H., & Os, I. (2005) · Blood Pressure · doi:10.1080/08037050510008959 · Cited by 17
Metadata
- Authors
- Mogensen, C. E., Neldam, S., Tikkanen, I., Oren, S., Viskoper, R., Watts, R. W., & Cooper, M. E.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2000-12-09
- Volume
- 321
- Issue
- 7274
- Pages
- 1440-1444
- ISSN
- 0007-1447 (ISSN-L)
- 0959-8138
- 1468-5833
- OpenAlex
- W2084343172
- Cited by
- 1,037
- References
- 33
- FWCI
- 49.58
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.